传染科

订阅

MedSci主页 / 所有栏目 / 传染科

CID：脑膜炎球菌B疫苗对青少年侵袭性脑膜炎的影响。

2021-09-29 从医路漫漫 MedSci原创

脑膜炎球菌B疫苗侵袭性脑膜炎
关注

由脑膜炎奈瑟菌引起的侵袭性脑膜炎球菌病(IMD)仍然是世界范围内发病率和死亡率的重要原因。

背景:自2017年起，在南澳大利亚开展了一项全州范围的随机试验，以评估脑膜炎球菌B疫苗4CMenB对青少年咽部脑膜炎奈瑟菌携带的影响。由脑膜炎奈瑟菌引起的侵袭性脑膜炎球菌病(IMD)仍然是世界范围内发病率和死亡率的重要原因。在澳大利亚、欧洲、北美和南美洲，大部分IMD病例是由B群脑膜炎引起的。高中生在2017年(干预)或2018年(对照)随机接种疫苗。在这项研究中，我们报道了4CMenB疫苗对南澳大利亚16- 19岁青少年B血清群侵袭性脑膜炎球菌病(IMD)的影响。

方法。这项对血清组B IMD病例的观察性时间序列分析比较了试验开始前14年(2003-2016年)与2017年接种4CMenB疫苗后2年的青少年队列。

结果。在南澳大利亚州，大约62%的10年级和11年级学生(15-16岁)参加了试验。总共有30 522名10-12岁的学生接受了至少1剂4CMenB。从2003年到2016年，南澳大利亚州16- 19岁青少年中血清B组IMD病例的数量平均每年增加10%(95%置信区间[CI]， 6%-15%， P < .001)， 2015年达到峰值，10例。血清组B IMD病例在2017-2018年减少到5例，在2018-2019年减少到1例，分别低于9.9(95%预测区间[PI]，3.9-17.5)和10.9 (95% PI, 4.4-19.1)的预期数字。这意味着血清B组IMD病例总数减少了71% (95% CI, 15%-90%，P =0 .02)。在接种疫苗的青少年中没有血清组B型IMD病例。

图 根据符合研究前阶段(2003-2016)并延续4CMenB至高中阶段(2017-2018年至2018-2019年)的趋势线，在南澳大利亚观察和预测B组侵袭性脑膜炎球菌病(IMD)病例，0-4岁和16-19岁年龄组的预测间隔为95%。缩写：MenB，脑膜炎球菌B。

结论。在南澳大利亚，青少年接种4CMenB疫苗与B组脑膜炎球菌病的减少有关。

原文出处：

McMillan M,  Wang B,  Koehler AP, et al,Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents.Clin Infect Dis 2021 07 01;73(1)

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991643, encodeId=ea7319916433d, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jan 25 23:51:12 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058438, encodeId=0de510584381c, content=很好的医学知识，感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95025575812, createdName=临床小白, createdTime=Thu Oct 07 19:43:02 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366394, encodeId=11f81366394ea, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 01 14:51:12 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056765, encodeId=3f251056e657f, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:58 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056426, encodeId=5606105642641, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Thu Sep 30 11:22:13 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2022-01-25 xlxchina

    #CID#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1991643, encodeId=ea7319916433d, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jan 25 23:51:12 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058438, encodeId=0de510584381c, content=很好的医学知识，感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95025575812, createdName=临床小白, createdTime=Thu Oct 07 19:43:02 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366394, encodeId=11f81366394ea, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 01 14:51:12 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056765, encodeId=3f251056e657f, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:58 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056426, encodeId=5606105642641, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Thu Sep 30 11:22:13 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-10-07 临床小白

    很好的医学知识，感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1991643, encodeId=ea7319916433d, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jan 25 23:51:12 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058438, encodeId=0de510584381c, content=很好的医学知识，感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95025575812, createdName=临床小白, createdTime=Thu Oct 07 19:43:02 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366394, encodeId=11f81366394ea, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 01 14:51:12 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056765, encodeId=3f251056e657f, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:58 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056426, encodeId=5606105642641, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Thu Sep 30 11:22:13 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-10-01 sunyl07

    #侵袭性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1991643, encodeId=ea7319916433d, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jan 25 23:51:12 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058438, encodeId=0de510584381c, content=很好的医学知识，感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95025575812, createdName=临床小白, createdTime=Thu Oct 07 19:43:02 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366394, encodeId=11f81366394ea, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 01 14:51:12 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056765, encodeId=3f251056e657f, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:58 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056426, encodeId=5606105642641, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Thu Sep 30 11:22:13 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-10-01 13f0c37dm61暂无昵称

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1991643, encodeId=ea7319916433d, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jan 25 23:51:12 CST 2022, time=2022-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058438, encodeId=0de510584381c, content=很好的医学知识，感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95025575812, createdName=临床小白, createdTime=Thu Oct 07 19:43:02 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366394, encodeId=11f81366394ea, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Fri Oct 01 14:51:12 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056765, encodeId=3f251056e657f, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:58 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056426, encodeId=5606105642641, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d3a4700555, createdName=595690844, createdTime=Thu Sep 30 11:22:13 CST 2021, time=2021-09-30, status=1, ipAttribution=)]
    2021-09-30 595690844

    学习了

    0